| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
1 Department of Gastroenterology, Rui-jin Hospital, Shanghai Second Medical University, Shanghai, People’s Republic of China,
2 Department of Medicine
3 Institute of Molecular Biology, University of Hong Kong, Hong Kong Special Administration Region, People’s Republic of China
Survivin plays an important role in cancer development. We aim to show here that suppression of survivin expression or function by antisense and dominant-negative (DN) mutant can inhibit gastric cancer carcinogenesis and angiogenesis in vivo. Plasmid constructs expressing survivin antisense and DN mutant replacing the cysteine residue at amino acid 84 with alanine (Cys84Ala) were prepared and introduced into BCG-823 and MKN-45 gastric cancer cells to establish stable transfectants. We showed that both antisense and DN mutant stable transfectants exhibited abnormal morphology, with decreased cell growth and increased rate of spontaneous apoptosis and mitotic catastrophe. Furthermore, in nude mice xenografts, these cells exhibited decreased de novo gastric tumor formation and reduced development of angiogenesis. Results from these studies strongly suggest that survivin is a promising target for gastric cancer treatment.
This article has been cited by other articles:
|
|
 |
|
  L. Wang, Q. Zhang, B. Liu, M. Han, and B. Shan Challenge and promise: roles for Livin in progression and therapy of cancer Mol. Cancer Ther., December 1, 2008; 7(12): 3661 - 3669. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X.-F. Wang, J. Kerzerho, O. Adotevi, H. Nuyttens, C. Badoual, G. Munier, S. Oudard, S. Tu, E. Tartour, and B. Maillere Comprehensive Analysis of HLA-DR- and HLA-DP4-Restricted CD4+ T Cell Response Specific for the Tumor-Shared Antigen Survivin in Healthy Donors and Cancer Patients J. Immunol., July 1, 2008; 181(1): 431 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Y. Chun, Y. Hu, E. Pinder, J. Wu, F. Li, and A. C. Gao Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter Mol. Cancer Ther., September 1, 2007; 6(9): 2572 - 2580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Caldas, J. R. Fangusaro, D. R. Boue, M. P. Holloway, and R. A. Altura Dissecting the role of endothelial SURVIVIN {Delta}Ex3 in angiogenesis Blood, February 15, 2007; 109(4): 1479 - 1489. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-w. Wang, Y. Qu, J.-f. Li, X.-h. Chen, B.-y. Liu, Q.-l. Gu, and Z.-g. Zhu In vitro and In vivo Evidence of Metallopanstimulin-1 in Gastric Cancer Progression and Tumorigenicity. Clin. Cancer Res., August 15, 2006; 12(16): 4965 - 4973. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Zhu, L. Gu, H. W. Findley, C. Chen, J.-T. Dong, L. Yang, and M. Zhou KLF5 Interacts with p53 in Regulating Survivin Expression in Acute Lymphoblastic Leukemia J. Biol. Chem., May 26, 2006; 281(21): 14711 - 14718. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Ryan, G. E. Konecny, S. Kahlert, H.-J. Wang, M. Untch, G. Meng, M. D. Pegram, K. C. Podratz, J. Crown, D. J. Slamon, et al. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1 Ann. Onc., April 1, 2006; 17(4): 597 - 604. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Bhonde, M.-L. Hanski, J. Budczies, M. Cao, B. Gillissen, D. Moorthy, F. Simonetta, H. Scherubl, M. Truss, C. Hagemeier, et al. DNA Damage-induced Expression of p53 Suppresses Mitotic Checkpoint Kinase hMps1: THE LACK OF THIS SUPPRESSION IN p53MUT CELLS CONTRIBUTES TO APOPTOSIS J. Biol. Chem., March 31, 2006; 281(13): 8675 - 8685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H Caldas, M P Holloway, B M Hall, S J Qualman, and R A Altura Survivin-directed RNA interference cocktail is a potent suppressor of tumour growth in vivo J. Med. Genet., February 1, 2006; 43(2): 119 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Wu, X. Ling, D. Pan, P. Apontes, L. Song, P. Liang, D. C. Altieri, T. Beerman, and F. Li Molecular Mechanism of Inhibition of Survivin Transcription by the GC-rich Sequence-selective DNA Binding Antitumor Agent, Hedamycin: EVIDENCE OF SURVIVIN DOWN-REGULATION ASSOCIATED WITH DRUG SENSITIVITY J. Biol. Chem., March 11, 2005; 280(10): 9745 - 9751. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Schimmer and S. Dalili Targeting the IAP Family of Caspase Inhibitors as an Emerging Therapeutic Strategy Hematology, January 1, 2005; 2005(1): 215 - 219. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Schimmer Inhibitor of Apoptosis Proteins: Translating Basic Knowledge into Clinical Practice Cancer Res., October 15, 2004; 64(20): 7183 - 7190. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
